Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma

Cancer Research

Volumn 64, Issue 23, 2004, Pages 8773-8777

  DiVito, Kyle A ^a   Berger, Aaron J ^a   Camp, Robert L ^a   Dolled Filhart, Marisa ^a   Rimm, David L ^a   Kluger, Harriet M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; COMPLEMENTARY DNA; CY5 CONJUGATED ANTIBODY; DACARBAZINE; PROTEIN BCL 2; PROTEIN S 100; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOMATED QUANTITATIVE ANALYSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTINUOUS INDEX SCORE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSESSMENT OF PROTEIN EXPRESSION; SCORING SYSTEM; STAINING;

COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 9244229046     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1387     Document Type: Article

References (37)

1. Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367-71.
2. Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999;17:1884-90.
3. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998;16:1743-51.
4. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
5. Margolin KA, Liu PY, Flaherty LE, et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998;16:664-9.
6. Markovic S, Suman VJ, Dalton RJ, et al. Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma. Am J Clin Oncol 2002;25:552-6.
7. Tsujimoto Y. Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep 2002;22:47-58.
8. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science (Wash DC) 1998;281:1322-6.
9. Bush JA, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003;20:531-9.
10. Olie RA, Hafner C, Kuttel R, et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Investig Dermatol 2002;118:505-12.
11. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000;292:225-32.
12. Sviatoha V, Rundgren A, Tani E, Hansson J, Kleina R, Skoog L. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma. Cytopathology 2002;13:11-21.
13. Utikal J, Leiter U, Udart M, Kaskel P, Peter RU, Krahn GM. Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma. Cancer Investig 2002;20:914-21.
14. van den Oord JJ, Vandeghinste N, De Ley M, De Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994;145:294-300.
15. Saenz-Santamaria MC, Reed JA, McNutt NS, Shea CR. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol 1994;21:393-7.
16. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995;8:150-4.
17. Tron VA, Krajewski S, Klein-Parker H, Li G, Ho VC, Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am J Pathol 1995;146:643-50.
18. Tang L, Tron VA, Reed JC, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998;4:1865-71.
19. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004;164:193-203.
20. Cerroni L, Soyer HP, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 1995;17:7-11.
21. Plettenberg A, Ballaun C, Pammer J, et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am J Pathol. 1995;146:651-9.
22. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R, Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998;8:197-203.
23. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
24. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
25. Berger AJ, Kluger HM, Li N, et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 2003;63:8103-7.
26. Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative determination of expression of the prostate alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol 2004;164:831-40.
27. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 2003;63:1445-8.
28. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999;26:78-83.
29. Avivi I, Robinson S, and Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer 2003;89:1389-94.
30. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer 2002;38 Suppl 5:S52-9.
31. Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001;62-6.
32. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-23.
33. Gewirtz AM. Oligonucleotide therapeutics: a step forward. J Clin Oncol 2000;18:1809-11.
34. Griffin TJ, Gygi SP, Ideker T, et al. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002;1:323-33.
35. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999;19:1720-30.
36. Gygi SP, Rist B, Aebersold R. Measuring gene expression by quantitative proteome analysis. Curr Opin Biotechnol 2000;11:396-401.
37. Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-83.